Immunocore Holdings plc (NasdaqGS: IMCR)
Health Care · Biotechnology · GB
$36.88
+7.80% today · +13.2% 1Y
Immunocore Holdings plc (NasdaqGS: IMCR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $1.90B and employs 524 people.
Over the last twelve months the share price has gained 13.2%, trading between 27.56 and 40.71.
Tweenvest scores Immunocore Holdings plc across four factors: quality 47/100, value 64/100, growth 100/100. Its strongest factor is growth.
IMCR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $1.90B
- Revenue (TTM)
- $430.77M
- P/E
- —
- EPS
- -0.36
- Dividend yield
- —
- Beta (5Y)
- 0.74
- 52-week high
- $40.71
- 52-week low
- $27.56
- Avg volume (3M)
- —
- Shares outstanding
- 51.50M
- Employees
- 524
- Next earnings
- —
About Immunocore Holdings plc
Immunocore Holdings plc, a biotechnology firm established in 1999 and based in Abingdon, United Kingdom, has reached the commercial stage in its mission to create pioneering immunotherapies. The company's development pipeline addresses a range of serious conditions, including various cancers, infectious diseases, and autoimmune disorders. Its currently marketed product, KIMMTRAK, offers a treatment option for patients with uveal melanoma that is either unresectable or has metastasized. Within oncology, Immunocore is progressing IMC-C103C through early-stage (Phase I/II) dose escalation trials for several solid tumor types, notably non-small-cell lung (NSCLC), gastric, head and neck, ovarian, and synovial sarcoma cancers. Another key oncology program, IMC-F106C, is also in Phase I/II dose escalation studies for a diverse array of solid malignancies, including NSCLC, small-cell lung, endometrial, ovarian, cutaneous melanoma, and breast cancers. For infectious diseases, the company is advancing IMC-I109V in Phase I/II clinical trials for chronic hepatitis B virus, alongside IMC-M113V, which is undergoing preclinical development for human immunodeficiency virus (HIV). Additionally, Immunocore is developing novel therapeutic candidates designed to deliver precise, targeted immunosuppression as a treatment strategy for autoimmune conditions.
- Founded
- 1999
- Listed since
- Feb 5, 2021
- Exchange
- Nasdaq Global Select
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €883.80 | -2.02% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $142.62 | -1.69% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.